Clinical trial • Phase I • Oncology
ABBV-400 for Locally advanced or metastatic solid tumors
Phase I trial of ABBV-400 for Locally advanced or metastatic solid tumors. open-label. 160 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Locally advanced or metastatic solid tumors
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 24-04-2024
- First CTIS Authorization Date
- 30-07-2024
Trial design
open-label Phase I trial across 15 sites in France, Spain.
- Open Label
- Yes
- Target Sample Size
- 160
- Trial Duration For Participant
- 1460
Eligibility
Recruits 160 No vulnerable populations selected; consent/assent handling not specified.
- Vulnerable Population
- No vulnerable populations selected; consent/assent handling not specified
Recruitment
- Planned Sample Size
- 160
- Recruitment Window Months
- 23
Geography
- Total Number Of Sites
- 15
- Total Number Of Participants
- 60
France
- Earliest CTIS Part Ii Submission Date
- 01-07-2024
- Latest Decision Or Authorization Date
- 29-07-2024
- Processing Time Days
- 28
- Number Of Sites
- 6
- Number Of Participants
- 24
Sites
- Site Name
- Centr Georges Francois Leclerc
- Department Name
- 403 : Medical Oncology
- Principal Investigator Name
- Francois Ghiringhelli
- Principal Investigator Email
- fghiringhelli@cgfl.fr
- Contact Person Name
- Francois Ghiringhelli
- Contact Person Email
- fghiringhelli@cgfl.fr
- Site Name
- Institut De Cancerologie De L Ouest
- Department Name
- 402 : Medical Oncology
- Principal Investigator Name
- Judith Raimbourg
- Principal Investigator Email
- judith.raimbourg@ico.unicancer.fr
- Contact Person Name
- Judith Raimbourg
- Contact Person Email
- judith.raimbourg@ico.unicancer.fr
- Site Name
- Institut Bergonie
- Department Name
- 404 : Medical Oncology
- Principal Investigator Name
- Sophie COUSIN
- Principal Investigator Email
- s.cousin@bordeaux.unicancer.fr
- Contact Person Name
- Sophie COUSIN
- Contact Person Email
- s.cousin@bordeaux.unicancer.fr
- Site Name
- Institut Curie
- Department Name
- 405 : Department of Drug Development and Innovation
- Principal Investigator Name
- Marie-Paule Sablin
- Principal Investigator Email
- mariepaule.sablin@curie.fr
- Contact Person Name
- Marie-Paule Sablin
- Contact Person Email
- mariepaule.sablin@curie.fr
- Site Name
- Centre Leon Berard
- Department Name
- 401 : Department of Medical Oncology
- Principal Investigator Name
- Aurelie Swalduz
- Principal Investigator Email
- aurelie.swalduz@lyon.unicancer.fr
- Contact Person Name
- Aurelie Swalduz
- Contact Person Email
- aurelie.swalduz@lyon.unicancer.fr
- Site Name
- Institut Gustave Roussy
- Department Name
- 400 : DITEP Drug Development Department
- Principal Investigator Name
- Antoine Hollebecque
- Principal Investigator Email
- antoine.hollebecque@gustaveroussy.fr
- Contact Person Name
- Antoine Hollebecque
- Contact Person Email
- antoine.hollebecque@gustaveroussy.fr
Spain
- Earliest CTIS Part Ii Submission Date
- 17-07-2024
- Latest Decision Or Authorization Date
- 26-01-2026
- Processing Time Days
- 558
- Number Of Sites
- 9
- Number Of Participants
- 36
Sites
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- 606 : Oncología Médica
- Principal Investigator Name
- Elena Garralda Cabanas
- Principal Investigator Email
- egarralda@vhio.net
- Contact Person Name
- Elena Garralda Cabanas
- Contact Person Email
- egarralda@vhio.net
- Site Name
- Clinica Universidad De Navarra
- Department Name
- 605 : Oncología Medica
- Principal Investigator Name
- Ana Landa Magdalena
- Principal Investigator Email
- alandam@unav.es
- Contact Person Name
- Ana Landa Magdalena
- Contact Person Email
- alandam@unav.es
- Site Name
- Clinica Universidad De Navarra (Madrid)
- Department Name
- 610 : Oncología
- Principal Investigator Name
- Ana Landa Magdalena
- Principal Investigator Email
- alandam@unav.es
- Contact Person Name
- Ana Landa Magdalena
- Contact Person Email
- alandam@unav.es
- Site Name
- Hospital Universitario Fundacion Jimenez Diaz
- Department Name
- 600 : Oncología
- Principal Investigator Name
- Bernard Gaston Doger De Speville Uribe
- Principal Investigator Email
- bernard.doger@startmadrid.com
- Contact Person Name
- Bernard Gaston Doger De Speville Uribe
- Contact Person Email
- bernard.doger@startmadrid.com
- Site Name
- Institut Catala D'oncologia
- Department Name
- 609 : Oncología Médica
- Principal Investigator Name
- Cinta Hierro Carbó
- Principal Investigator Email
- chierro@iconcologia.net
- Contact Person Name
- Cinta Hierro Carbó
- Contact Person Email
- chierro@iconcologia.net
- Site Name
- Hospital Universitario Hm Sanchinarro
- Department Name
- 602 : Oncología Médica
- Principal Investigator Name
- Juan Jose Soto
- Principal Investigator Email
- juanj.soto@startresearch.com
- Contact Person Name
- Juan Jose Soto
- Contact Person Email
- juanj.soto@startresearch.com
- Site Name
- Hospital General Universitario Gregorio Maranon
- Department Name
- 607 : Neumología
- Principal Investigator Name
- Aitana Calvo Ferrándiz
- Principal Investigator Email
- pilaraitanacalvo@salud.madrid.org
- Contact Person Name
- Aitana Calvo Ferrándiz
- Contact Person Email
- pilaraitanacalvo@salud.madrid.org
- Site Name
- Hospital Hm Nou Delfos
- Department Name
- 608 : Oncología
- Principal Investigator Name
- Tatiana Hernández Guerrero
- Principal Investigator Email
- tatiana.hernandez@start-barcelona.com
- Contact Person Name
- Tatiana Hernández Guerrero
- Contact Person Email
- tatiana.hernandez@start-barcelona.com
- Site Name
- Hospital Universitario (additional site)
Sponsor
Primary sponsor
- Full Name
- AbbVie Deutschland GmbH & Co. KG
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Germany
Investigational products
- Investigational Product Name
- ABBV-400
Related trials
Other published trials that may interest you.
- PATRITUMAB DERUXTECAN for Locally advanced or metastatic solid tumors
- XmAb24306 for Locally advanced or metastatic solid tumors
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer